Key result
A single 500 ng dose of exogenous Interleukin-12 increased the survival rate of mice lethally infected with Coxsackievirus B4 to 85%, compared to 0% in untreated controls.
Why the study?
Does exogenous IL-12 improve survival in mice infected with lethal Coxsackievirus B4?
Does exogenous IL-12 improve survival in mice infected with lethal Coxsackievirus B4?
Answers are grounded in this paper and cite their sources.
Exogenous IL-12 protects mice against lethal Coxsackievirus B4 infection and prevents chronic pancreatitis by inducing IFN-gamma production.
Infections with the group B coxsackieviruses either can be asymptomatic or can lead to debilitating chronic diseases. To elucidate the mechanism by which these viruses cause chronic disease, we developed a mouse model of chronic pancreatitis by using a virulent variant of coxsackievirus B4, CVB4-V. Infection with CVB4-V results in an early, severe pancreatitis, which can lead to mortality or progress to chronic pancreatitis. Chronic pancreatitis, in this model, is due to immunopathological mechanisms. We investigated whether interleukin-12 (IL-12) could modulate the outcome of CVB4-V infection. Eighty-five percent of the infected mice treated with 500 ng of IL-12 survived, whereas all untreated mice succumbed. To understand the mechanism underlying the beneficial effect of IL-12, we investigated the role of gamma interferon (IFN-gamma). Three lines of evidence suggest that the protective effect of IL-12 is due to IFN-gamma. First, administration of IL-12 increased the production of endogenous IFN-gamma in CVB4-V-infected mice. Both NK and NKT cells were identified as the source of IFN-gamma. Second, IFN-gamma knockout mice treated with IL-12 succumbed to infection with CVB4-V. Third, wild-type mice treated with IFN-gamma survived infection with CVB4-V. Due to the antiviral effects of IFN-gamma, we examined whether IL-12 treatment affected viral replication. Administration of IL-12 did not decrease viral replication in the pancreas, but it did prevent extensive tissue damage and the subsequent development of chronic pancreatitis. The data suggest that IL-12 treatment during CVB4-V infection is able to suppress the immunopathological mechanisms that lead to chronic disease.
No takes yet. Share an insight, caveat, or question.
Potvin et al. (2003) studied Coxsackievirus B4 infection (n=41). Interleukin-12 vs. Vehicle alone was evaluated on Survival (p=<0.001). A single 500 ng dose of exogenous Interleukin-12 increased the survival rate of mice lethally infected with Coxsackievirus B4 to 85%, compared to 0% in untreated controls.
Synapse has enriched 10 related papers. Consider them for comparative context: